Anaphylaxis management is falling short in 2026 - EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed-and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data suggests only around half of patients consistently carry their prescribed AAI, with adherence perceived to be lowest among adolescents.2EURneffy®, the only needle-free nasal adrenaline spray, was strongly and consistently preferred over AAIs by patients across four countries in a discrete choice experi